➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Dow
Johnson and Johnson
McKinsey
Boehringer Ingelheim
AstraZeneca

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Litigation Details for JAZZ PHARMACEUTICALS, INC. v. ROXANE LABORATORIES, INC. (D.N.J. 2010)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

JAZZ PHARMACEUTICALS, INC. v. ROXANE LABORATORIES, INC. (D.N.J. 2010)

Docket   Start Trial Date Filed 2010-11-22
Court District Court, D. New Jersey Date Terminated
Cause 35:183 Patent Infringement Assigned To Esther Salas
Jury Demand None Referred To Michael A. Hammer
Parties ROXANE LABORATORIES, INC.
Patents 6,780,889; 7,262,219; 7,668,730; 7,765,106; 7,765,107; 7,851,506; 7,895,059; 8,263,650; 8,324,275; 8,457,988
Attorneys WILLIAM C. BATON
Firms Hogan Lovells US LLP
Link to Docket External link to docket
Small Molecule Drugs cited in JAZZ PHARMACEUTICALS, INC. v. ROXANE LABORATORIES, INC.
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for JAZZ PHARMACEUTICALS, INC. v. ROXANE LABORATORIES, INC. (D.N.J. 2010)

Date Filed Document No. Description Snippet Link To Document
2010-11-22 1 States Patent Nos. 6,780,889 (the “’889 patent”), 7,262,219 (the “’219 patent”), 7,668,730 (the “’730… 1. This is an action for patent infringement under the patent laws of the United States, 35 …’730 patent”), 7,765,106 (the “’106 patent”), Case 2:10-cv-06108-ES-SCM Document 1 Filed 11/22/10 Page…7,765,107 (the “’107 patent”) owned by Jazz Pharmaceuticals (collectively, “the patents- in-suit”). … The Patents in Suit 8. On August 24, 2004, the United States Patent and Trademark External link to document
2012-07-30 136 oxybate product: U.S. Patent Nos. 6,472,431 (the “431 patent”), 6,780,889 (the “889 patent”), 7,262,219 (the…(the “219 patent”), and 7,851,506 (the “506 patent”) (collectively, the “Product Patents”); and (2) … product: U.S. Patent Nos. 7,668,730 (the “730 patent”), 7,765,106 (the “106 patent”), 7,765, 107 …the “107 patent”), and 7,895,059 (the “059 patent”) (collectively, the “Distribution Patents”). (Id.…context of patent litigation, Federal Circuit precedent governs the interpretation of local patent rules External link to document
2012-09-14 151 United States Patent Nos. 6,472,431 (the “‘431 patent”), 6,780,889 (the “‘889 patent”), 7,262,219 (… (the “‘219 patent”), and 7,851,506 (the “‘506 patent”), (collectively, the “‘431 patent family” or …,730 (the “‘730 patent”), 7,765,106 (the “‘106 patent”), 7,765,107 (the “‘107 patent”) and 7,895,059…1 of the ‘431 patent, claim 1 of the ‘889 patent, and claims 1 and 4 of the ‘219 patent. …5 of the ‘431 patent, claim 1 of the ‘889 patent, claims 1, 2, and 4 of the ‘219 patent, and claim 1 External link to document
2012-09-28 156 et al' TI'IE TREATMENT OF NARCOLEPSY 6,780,889 32 * 8/2004 cook or ai. .................... 514…gt;' Am@ndmenf filed M"fy 8- Pat. No. 6,780,889, which is a division of application §§0; ‘A4 pigs…2002 and issued onAug. 24, 2004 as U.S. Pat. No. 6,780, 889, which is a divisional of U.S. application Ser…Office (“PTO”) issued a ninth patent, U.S. Patent No. 8,263,650 (“the ‘650 patent”) that is a continuation … Page 2 to U.S. Patent No. 6,472,431, the first of four patents in the “‘431 patent family” that are External link to document
2012-10-02 159 XYREM®. 2 The patents-in-suit are U.S. Patent Nos. 6,472,431, 6,780,889, 7,262,219, 7,851,506,…information regarding the subject matter of the patents- -in-suit, _ All of his confidentiality agreements… 2, 2012 Page 2 I. BACKGROUND This action for patent infringement stems from Roxane’ s efforts to market…and cataplexy 1n patients With narcolepsy. The patents- -in-suit2 concern formulations containing sodium…narcolepsy patients-the subject matter of certain patents-in-suit. (See Ex. A at col. 72, lns. 19- 37.) External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Express Scripts
Moodys
McKesson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.